default author photo

Joong-Won Park

National Cancer Center, Korea

Seoul, 100-715

Korea, Republic of (South Korea)

SCHOLARLY PAPERS

2

DOWNLOADS

310

TOTAL CITATIONS

7

Scholarly Papers (2)

1.

Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial

Number of pages: 47 Posted: 16 Aug 2021
The University of Hong Kong, National Cancer Center, Korea, University of California, Los Angeles (UCLA) - David Geffen School of Medicine, National Taiwan University - Department of Internal Medicine, Anger University Hospital - HepatoGastroenterology Department, Centre Eugène Marquis - Medical Oncology, Kindai University - Department of Gastroenterology and Hepatology, Memorial Sloan Kettering Cancer Center - Department of Medicine, Croix Rousse Hospital - Hepatology Unit, Sorbonne University - ssistance Publique Hôpitaux de Paris, M. Sklodowska-Curie Memorial National Cancer Research Institute, University Hospital Ulm - Helios Klinikum Emil von Behring GmbH, National Cancer Centre Singapore - Division of Medical Oncology, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, Medical University of Vienna - Department of Internal Medicine III, Hôpital Avicenne (APHP) - Centre Hospitalier Universitaire de Montpellier,, Medical University of Gdańsk - Department of Clinical Oncology and Radiotherapy, Kyorin University - Department of Medical Oncology, Memorial Sloan Kettering Cancer Center - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center, University of Navarra - Department of Cardiology and Cardiovascular Surgery, Bristol Myers Squibb, Bristol Myers Squibb, Bristol Myers Squibb, Bristol Myers Squibb, Bristol Myers Squibb and Carlos III National Institute of Health - Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd)
Downloads 241 (316,532)
Citation 6

Abstract:

Loading...

hepatocellular carcinoma, liver cancer, nivolumab, PD-1 inhibitor, sorafenib, immuno-oncology, CheckMate

2.

Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study

Number of pages: 35 Posted: 08 Feb 2020
Kindai University - Department of Gastroenterology and Hepatology, University of California, Los Angeles (UCLA) - David Geffen School of Medicine, Nanjing Bayi Hospital, Yonsei University - Severance Hospital, Toranomon Hospital - Department of Hepatology, National Taiwan University - Department of Internal Medicine, University of Bologna, Kindai University - Faculty of Medicine, Hiroshima University - Hiroshima University Hospital, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hospital Marqués de Valdecilla, Comprehensive Cancer Center Eugène Marquis, Fudan University - Shanghai Cancer Center (FUSCC), Azienda Ospedaliera G. Rummo, National Cancer Center, Korea, Clatterbridge Cancer Centre, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc., Eisai, Inc. - Eisai, Inc. - United States and University of Miami - Miller School of Medicine
Downloads 69 (883,195)
Citation 1

Abstract:

Loading...

landmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint